Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation

Transplant Proc. 2001 May;33(3):2258-62. doi: 10.1016/s0041-1345(01)01983-2.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Azathioprine / therapeutic use
  • Drug Therapy, Combination
  • Ethnicity
  • Female
  • Graft Rejection / drug therapy
  • Graft Rejection / epidemiology
  • Graft Rejection / pathology
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / therapeutic use*
  • Liver Transplantation / immunology*
  • Liver Transplantation / mortality
  • Liver Transplantation / physiology
  • Male
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Patient Selection
  • Reoperation
  • Safety
  • Survival Rate
  • Tacrolimus / adverse effects
  • Tacrolimus / blood
  • Tacrolimus / therapeutic use*
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Azathioprine
  • Tacrolimus